Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.
In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces have developed consensus statements for genitourinary malignancies (renal and prostate carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia). An update of the melanoma consensus statement and new guidelines for bladder and lung cancers are also underway.
Click here for a complete listing of the guidelines and links to view.
SITC is the first and only organization dedicated to cancer immunotherapy to be accepted as a formal member of the Commission on Cancer (CoC), a program of the American College of Surgeons.
The CoC is the nation’s leading accreditation body for cancer care and has established a strong partnership approach to defining and measuring quality as it relates to managing patients with cancer. Today, more than 80 percent of Americans with cancer will seek treatment at a CoC accredited facility.
SITC represents leaders of the field of cancer immunotherapy, to help establish and implement immunotherapy at CoC-accredited institutions and develop mechanisms for collecting data and educating healthcare providers on the optimal way to deliver immunotherapy. SITC Immediate Past President, Howard Kaufman, MD, FACS, of the Rutgers Cancer Institute of New Jersey, serves as SITC’s official liaison to the Commission.
SITC has been a key collaborator in the development of the Foundation for the Accreditation of Cellular Therapy (FACT) Standards for Immune Effector Cell Administration.Marcela Maus, MD, PhD of Harvard Medical School serves as SITC’s official liaison to the FACT CAR-T Cell Task Force.
SITC provided formal comments to the FACT draft of the 1st edition FACT Standards for Immune Effector Cell Administration. These standards are intended to promote quality in the administration of immune effector cells and will be incorporated into a voluntary FACT accreditation in this field.
Click here to download "Standards for Immune Effector Cell Administration".
We have a patient with multiple brain metastases from melanoma beginning to develop symptoms (mental slowing and right facial droop) as we try to get him precerted for checkpoint inhibitor therapy. Any thoughts/anecdotes/data about how much if any ...
Did you know there are more than 800 resources available to SITC members? Access by your user type ( researcher , clinician , patient ) or by using the SITC Cancer Immunotherapy CONNECT Search (top right) to find exactly what you're looking ...
In light of what can occur in the TME in the steady state, malignant cells killed by intrinsic/extrincic stress factors in it can lead to danger-associated molecular patterns (e.g. HMGB-1) and plasma membrane exposure of the endoplasmic reticulum (ER) ...
Thank you everyone.Very helpful. ------------------------------ Jane Gutkovich Director of Research The EHE Foundation Woodbridge VA ------------------------------
As I am not a physician I do not have direct experience with the situation you describe. Nevertheless, I found information indicating that about two-thirds of patients develop symptoms of neurological dysfunction secondary to paraneoplastic neurological ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com